The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of three doses of LP-10
(intravesical tacrolimus). Twelve subjects meeting the inclusion and exclusion criteria will
be enrolled and treated in a prospective and multi-center trial with LP-10. The proposed
trial will recruit 12 subjects in a dose-escalation trial where 4 subjects will be allocated
into each one of three groups.